Skip to main content

Table 1 Clinical and pathologic data stratified by endometrioid versus serous histology

From: Utility of a custom designed next generation DNA sequencing gene panel to molecularly classify endometrial cancers according to The Cancer Genome Atlas subgroups

 

All (N = 47)

EAC (N = 34)

USC (N = 13)

OR (95% CI)b

p-value

Age (years)

63.6 ± 11.0

60.9 ± 11.2

70.7 ± 7.0

 

< 0.01

Parity (number of children)

2 (1, 4)

1 (0,3)

4 (2, 7)

 

< 0.01

Race/ethnicitya

 White

13 (27.7)

11 (32.4)

2 (15.4)

REF

0.08

 Black

14 (29.8)

6 (17.7)

8 (61.5)

7.33 (1.16–46.23)

 Asian

3 (6.4)

3 (8.8)

0 (0)

N/A

 Hispanic

8 (19.2)

7 (20.6)

2 (15.4)

1.57 (0.18–13.86)

Race/ethnicitya

 White

13 (33.3)

11 (40.7)

2 (16.7)

REF

0.13

 Non-White

26 (66.7)

16 (59.3)

10 (83.3)

3.44 (0.63–18.84)

Pregnancy history

 Nulliparous

11 (23.4)

11 (32.4)

0 (0)

REF

0.02

 Parous

36 (76.7)

23 (63.9)

13 (100.0)

N/A

 Personal history of malignancy

6 (12.8)

3 (8.82)

3 (23.1)

3.10 (0.54–18.87)

0.33

 Family history of malignancy

29 (61.7)

22 (64.7)

7 (53.9)

0.64 (0.17–2.32)

0.52

Tobacco use

 Never

35 (74.5)

24 (70.6)

11 (84.6)

REF

0.62

 Former

9 (19.2)

7 (20.6)

2 (15.4)

0.62 (0.11–3.50)

 Current

3 (6.4)

3 (8.8)

0 (0)

N/A

Metastatic disease

 Pelvic lymph nodes

9 (19.2)

4 (11.8)

5 (38.5)

5.00 (1.06–23.65)

0.09

 Para-aortic lymph nodes

8 (17.0)

2 (5.9)

6 (46.2)

8.50 (1.33–54.12)

 < 0.01

 Omentum

0 (0)

0 (0)

0 (0)

N/A

N/A

 Ovaries

6 (12.8)

4 (11.8)

2 (15.4)

1.50 (0.24–9.47)

0.74

 Fallopian tubes

2 (4.3)

0 (0)

2 (15.4)

N/A

0.07

 Cervix

17 (36.2)

7 (20.6)

10 (76.9)

12.86 (2.77–59.66)

 < 0.01

 Lower uterine segment

2 (4.3)

2 (5.8)

0 (0)

N/A

 > 0.90

 Lymphovascular invasion

18 (38.3)

11 (32.4)

7 (53.9)

2.44 (0.66–9.00)

0.18

 Cytology

1 (2.1)

1 (2.9)

0 (0)

N/A

 > 0.90

Myometrial invasion

 0%

5 (10.6)

5 (14.7)

0 (0)

REF

0.25

 1–33%

18 (38.3)

13 (38.2)

5 (38.5)

0.38 (0.08–1.93)

 34–66%

14 (29.8)

11 (32.4)

3 (23.1)

0.27 (0.05–1.62)

 67–100%

10 (21.3)

5 (14.7)

5 (38.5)

N/A

Stage

 I

23 (48.9)

22 (64.7)

1 (7.7)

REF

 < 0.01

 II

8 (17.0)

4 (11.8)

4 (30.8)

22.00 (1.92–251.54)

 III

15 (31.9)

7 (20.6)

8 (61.5)

25.14 (2.66–237.62)

 IV

1 (2.1)

1 (2.9)

0 (0)

N/A

Stage

 I–II

31 (66.0)

26 (76.5)

5 (38.5)

REF

0.02

 III–IV

16 (34.0)

8 (23.5)

8 (61.5)

5.20 (1.32–20.46)

Treatment

 Chemotherapy

25 (53.2)

12 (35.3)

13 (100.0)

N/A

 < 0.01

 External beam radiation therapy

22 (46.8)

11 (32.4)

11 (84.6)

11.50 (2.17–61.04)

 < 0.01

 Brachytherapy

24 (51.1)

14 (41.2)

10 (76.9)

4.76 (1.11–20.50)

0.03

 Recurrence or progression

15 (31.9)

7 (20.6)

8 (61.5)

6.17 (1.53–24.84)

0.01

 Progression free survival (months)

33 (15, 45)

37.5 (24, 48)

15 (5, 26)

 

 < 0.01

Vital status

 Alive

34 (72.3)

27 (79.4)

7 (53.9)

REF

0.06

 Dead

4 (8.5)

1 (2.94)

3 (23.1)

11.57 (1.04–128.97)

 Lost to follow-up

9 (19.2)

6 (17.7)

3 (23.1)

1.93 (0.38–9.71)

  1. Data with plus-minus values represent means ± standard deviation, otherwise reported as median (interquartile range). Categorical data are presented as N (%)
  2. EBRT external beam radiation therapy, LVSI positive lymphovascular space invasion
  3. aBased on 39 patients with available race/ethnicity information
  4. bRefers to the odds of individual covariates being associated with serous histology relative to endometrioid histology. N/A values indicate that odds ratios are incalculable as subgroups predict failure perfectly
Back to article page

BMC Medical Genomics

ISSN: 1755-8794

Contact us